drugset
drugset / Trial / NCT01820364

LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma

NCT01820364 ↗

Phase 2 Terminated 15 enrolled Array BioPharma
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of the Phase II CLGX818X2102 study is to assess the anti-tumor activity of LGX818 in combination with selected agents.

Timeline

Start
2013-11
Primary completion
2015-03
Completion
2015-03

Outcome

Outcome not reported

Stopped (Business): “Study was withdrawn due to scientific and business considerations.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Encorafenib Small molecule — Oral

Indications

melanoma